Skip to main content

Table 4 Comparison of JRS stage I with GAP stage I and GAP stage II/III

From: Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis

 

JRS stage I + GAP stage I

JRS stage I + GAP stage II/III

P value

Age, years

70.3 ± 7.1

73.3 ± 6.4

0.004

Sex, male/female

86/25

61/7

0.04

BMI, kg/m2

22.4 ± 3.8

20.8 ± 4.2

0.009

Smoking history, N/F/C

15/70/26

7/51/10

0.24

GAP staging (I/II/III)

111/0/0

0/58/10

< 0.0001

mMRC (0/1/2/3/4)

26/56/24/4/1

2/17/38/9/2

< 0.0001

PaO2, Torr

90.9 ± 9.3

89.1 ± 8.4

0.18

%FVC, %

91.3 ± 13.9

65.6 ± 15.9

< 0.0001

%DLco, %

76.1 ± 19.4

56.2 ± 18.5

< 0.0001

KL-6, U/ml

890 ± 546

1016 ± 643

0.16

SP-D, ng/ml

233 ± 134

333 ± 295

0.002

6MWD, m

417 ± 92

336 ± 94

< 0.0001

Lowest SpO2 on 6MWT, %

91.4 ± 3.9

88.2 ± 4.9

< 0.0001

  1. Data is presented as mean ± standard deviation. JRS, Japanese Respiratory Society; BMI, body mass index; N/F/C, never/former/current; GAP, gender–age–physiology; mMRC, modified Medical Research Council; PaO2, partial pressure of oxygen in arterial blood; FVC, forced vital capacity; DLco, diffusion capacity of the lungs for carbon monoxide; KL-6, Krebs von den Lungen-6; SP-D, surfactant protein-D; 6MWD, 6-min walking distance; SpO2, percutaneous oxygen saturation; 6MWT, 6-min walk test
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us